{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:55:28Z","timestamp":1794048928946,"version":"4.8.0"},"reference-count":104,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lipid-lowering agents and antiplatelet drugs are guideline-recommended standard treatment for secondary prevention of acute thrombotic events in patients with increased cardiovascular risk. Aspirin is the most frequently used antiplatelet drug, either alone or in combination with other antiplatelet agents (P2Y12 inhibitors), while statins are first-line treatment of hypercholesterolemia. The well-established mode of action of aspirin is inhibition of platelet-dependent thromboxane formation. In addition, aspirin also improves endothelial oxygen defense via enhanced NO formation and inhibits thrombin formation. Low-dose aspirin exerts in addition anti-inflammatory effects, mainly via inhibition of platelet-initiated activation of white cells.<\/jats:p><jats:p>Statins inhibit platelet function via reduction of circulating low-density lipoprotein-cholesterol (LDL-C) levels and a more direct inhibition of platelet function. This comprises inhibition of thromboxane formation via inhibition of platelet phospholipase A2 and inhibition of (ox)LDL-C-mediated increases in platelet reactivity via the (ox)LDL-C receptor (CD36). Furthermore, statins upregulate endothelial NO-synthase and improve endothelial oxygen defense by inhibition of NADPH-oxidase. PCSK9 antibodies target a serine protease (PCSK9), which promotes the degradation of the LDL-C receptor impacting on LDL-C plasma levels and (ox)LDL-C-receptor-mediated signaling in platelets similar to but more potent than statins.<\/jats:p><jats:p>These functionally synergistic actions are the basis for numerous interactions between antiplatelet and these lipid-lowering drugs, which may, in summary, reduce the incidence of atherothrombotic vascular events.<\/jats:p>","DOI":"10.1055\/s-0042-1758654","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T02:45:12Z","timestamp":1671158712000},"page":"166-176","source":"Crossref","is-referenced-by-count":17,"title":["Drug\u2013Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)"],"prefix":"10.1055","volume":"123","author":[{"given":"Karsten","family":"Schr\u00f6r","sequence":"first","affiliation":[{"name":"Institut f\u00fcr Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-7121","authenticated-orcid":false,"given":"Dietmar","family":"Trenk","sequence":"first","affiliation":[{"name":"Department Universit\u00e4ts-Herzzentrum, Klinik f\u00fcr Kardiologie und Angiologie Bad Krozingen, Klinische Pharmakologie, Universit\u00e4tsklinikum Freiburg, Bad Krozingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-6951","authenticated-orcid":false,"given":"Freek W. A.","family":"Verheugt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"issue":"24","key":"ref1","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"G Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"100694","DOI":"10.1016\/j.blre.2020.100694","article-title":"Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: potential role of antiplatelet agents","volume":"45","author":"R Lordan","year":"2021","journal-title":"Blood Rev"},{"issue":"03","key":"ref3","first-page":"469","article-title":"Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?","volume":"114","author":"T Hohlfeld","year":"2015","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/0002-9343(90)90220-8","article-title":"Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians","volume":"89","author":"J E Manson","year":"1990","journal-title":"Am J Med"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"P M Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/0002-8703(91)90275-M","article-title":"The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study","volume":"122","author":"P M Ridker","year":"1991","journal-title":"Am Heart J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0140-6736(92)93216-A","article-title":"Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study","volume":"340","author":"S Z Goldhaber","year":"1992","journal-title":"Lancet"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvu028","article-title":"Vessel wall, not platelet, P2Y12 potentiates early atherogenesis","volume":"102","author":"L E West","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis","volume":"181","author":"L C Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"e023085","DOI":"10.1136\/bmjopen-2018-023085","article-title":"Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews","volume":"9","author":"P Byrne","year":"2019","journal-title":"BMJ Open"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"n1537","DOI":"10.1136\/bmj.n1537","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses","volume":"374","author":"T Cai","year":"2021","journal-title":"BMJ"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archinte.164.1.40","article-title":"Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses","volume":"164","author":"C H Hennekens","year":"2004","journal-title":"Arch Intern Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.jacc.2018.09.052","article-title":"Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome: JACC state-of-the-art review","volume":"72","author":"G Gallone","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref14","first-page":"e177","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"D K Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1161\/STROKEAHA.121.034576","article-title":"Lipid-lowering therapy and hemorrhagic stroke risk: comparative meta-analysis of statins and PCSK9 inhibitors","volume":"52","author":"B E Sanz-Cuesta","year":"2021","journal-title":"Stroke"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6661847","DOI":"10.1155\/2021\/6661847","article-title":"Effect of statins on platelet activation and function: from molecular pathways to clinical effects","volume":"2021","author":"A Nenna","year":"2021","journal-title":"BioMed Res Int"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5551\/jat.RV17003","article-title":"PCSK9 and atherosclerosis - lipids and beyond","volume":"24","author":"M D Shapiro","year":"2017","journal-title":"J Atheroscler Thromb"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention","volume":"119","author":"F Paciullo","year":"2019","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"e13459","DOI":"10.1111\/eci.13459","article-title":"PCSK9 and atherosclerosis: Looking beyond LDL regulation","volume":"51","author":"R Ragusa","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.3390\/ijms22115880","article-title":"PCSK9 biology and its role in atherothrombosis","volume":"22","author":"C Barale","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"06","key":"ref21","first-page":"466","article-title":"Antiplatelet effects of PCSK9 inhibitors in primary hypercholesterolemia","volume":"11","author":"P P\u0119czek","year":"2021","journal-title":"Life (Basel)"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/metabo12030226","article-title":"Pleiotropic effects of PCSK9: focus on thrombosis and haemostasis","volume":"12","author":"M Puccini","year":"2022","journal-title":"Metabolites"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as positive modulator of platelet activation","volume":"71","author":"M Camera","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"ref24","doi-asserted-by":"crossref","first-page":"11179","DOI":"10.3390\/ijms222011179","article-title":"Platelet-derived PCSK9 is associated with LDL metabolism and modulates atherothrombotic mechanisms in coronary artery disease","volume":"22","author":"\u00c1 Petersen-Uribe","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Z Qi","year":"2021","journal-title":"Circulation"},{"issue":"18","key":"ref26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"M S Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"ref27","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"G G Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref28","first-page":"39","article-title":"Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia","volume":"2","author":"K Schr\u00f6r","year":"1989","journal-title":"Eicosanoids"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00315517","article-title":"The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study","volume":"45","author":"D Kaczmarek","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2011.02.026","article-title":"The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients","volume":"658","author":"B Luzak","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.etap.2016.01.002","article-title":"Lovastatin induces platelet apoptosis","volume":"42","author":"Q Zhao","year":"2016","journal-title":"Environ Toxicol Pharmacol"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cpt.1075","article-title":"Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease","volume":"104","author":"S Tacconelli","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jacc.2014.10.047","article-title":"The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome","volume":"65","author":"T R Sexton","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.thromres.2013.01.007","article-title":"Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms","volume":"131","author":"A Moscard\u00f3","year":"2013","journal-title":"Thromb Res"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2011.03.049","article-title":"Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting","volume":"58","author":"T Mattiello","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2009.07.039","article-title":"Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction","volume":"104","author":"M T Santos","year":"2009","journal-title":"Am J Cardiol"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1160\/TH14-01-0094","article-title":"Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin","volume":"112","author":"K P Bliden","year":"2014","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jdiacomp.2016.05.002","article-title":"Statin therapy and inflammation in patients with diabetes treated with high dose aspirin","volume":"30","author":"R Chaudhary","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00380-018-1193-6","article-title":"Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis","volume":"33","author":"T Konishi","year":"2018","journal-title":"Heart Vessels"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2174\/1573403X12666160504100312","article-title":"Anti-thrombotic effects of statins in acute coronary syndromes: at the intersection of thrombosis, inflammation, and platelet-leukocyte interactions","volume":"12","author":"T Sexton","year":"2016","journal-title":"Curr Cardiol Rev"},{"issue":"03","key":"ref41","first-page":"476","article-title":"Platelet hyperactivity after statin treatment discontinuation","volume":"90","author":"L Puccetti","year":"2003","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.0000012530.68333.C8","article-title":"Withdrawal of statins increases event rates in patients with acute coronary syndromes","volume":"105","author":"C Heeschen","year":"2002","journal-title":"Circulation"},{"issue":"13","key":"ref43","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCULATIONAHA.117.028321","article-title":"Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study","volume":"136","author":"J Sundstr\u00f6m","year":"2017","journal-title":"Circulation"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"976.e1","DOI":"10.1016\/j.ahj.2006.02.013","article-title":"Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial","volume":"151","author":"S Atar","year":"2006","journal-title":"Am Heart J"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40264-017-0552-z","article-title":"Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study","volume":"40","author":"K L Quinn","year":"2017","journal-title":"Drug Saf"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-015-1179-5","article-title":"Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand","volume":"40","author":"V Valdes","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/0363546519827294","article-title":"Effects of aspirin on growth factor release from freshly isolated leukocyte-rich platelet-rich plasma in healthy men: a prospective fixed-sequence controlled laboratory study","volume":"47","author":"P Jayaram","year":"2019","journal-title":"Am J Sports Med"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ijcard.2013.10.050","article-title":"Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction","volume":"170","author":"A Polzin","year":"2013","journal-title":"Int J Cardiol"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2011.04194.x","article-title":"Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation","volume":"9","author":"T Ulrych","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3109\/09537104.2011.553970","article-title":"The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy","volume":"22","author":"S Nomura","year":"2011","journal-title":"Platelets"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.05.001","article-title":"HMGB1 in health and disease","volume":"40","author":"R Kang","year":"2014","journal-title":"Mol Aspects Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3389\/fimmu.2017.01946","article-title":"From human megakaryocytes to platelets: effects of aspirin on high-mobility group box 1\/receptor for advanced glycation end products axis","volume":"8","author":"S Mardente","year":"2018","journal-title":"Front Immunol"},{"issue":"25","key":"ref53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/newbio231235a0","article-title":"Aspirin selectively inhibits prostaglandin production in human platelets","volume":"231","author":"J B Smith","year":"1971","journal-title":"Nat New Biol"},{"issue":"09","key":"ref54","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"D M Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.phrs.2016.04.001","article-title":"Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model","volume":"107","author":"E Tarantino","year":"2016","journal-title":"Pharmacol Res"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1055\/s-0038-1651063","article-title":"Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man\u2013effect of low-dose aspirin","volume":"57","author":"P A Kyrle","year":"1987","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/jth.12728","article-title":"Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid","volume":"12","author":"A Undas","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/blood.V80.8.2006.2006","article-title":"Antiplatelet drugs and generation of thrombin in clotting blood","volume":"80","author":"A Szczeklik","year":"1992","journal-title":"Blood"},{"issue":"08","key":"ref59","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/01.ATV.16.8.948","article-title":"Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia","volume":"16","author":"A Szczeklik","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.CIR.0000153810.81187.7D","article-title":"Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients","volume":"111","author":"V Sanguigni","year":"2005","journal-title":"Circulation"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00392-011-0282-7","article-title":"Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial","volume":"100","author":"A A Khattab","year":"2011","journal-title":"Clin Res Cardiol"},{"issue":"09","key":"ref62","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2005.11.058","article-title":"Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study)","volume":"97","author":"V L Serebruany","year":"2006","journal-title":"Am J Cardiol"},{"key":"ref63","doi-asserted-by":"crossref","DOI":"10.1515\/9783110746419","volume-title":"Acetylsalicylic Acid","author":"K Schr\u00f6r","year":"2022","edition":"3rd ed."},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2008.04.016","article-title":"Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse","volume":"202","author":"S McClelland","year":"2009","journal-title":"Atherosclerosis"},{"issue":"25","key":"ref65","doi-asserted-by":"crossref","first-page":"14916","DOI":"10.1074\/jbc.271.25.14916","article-title":"Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms","volume":"271","author":"D Pratic\u00f2","year":"1996","journal-title":"J Biol Chem"},{"issue":"24","key":"ref66","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/01.CIR.101.24.2833","article-title":"Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo","volume":"101","author":"L P Audoly","year":"2000","journal-title":"Circulation"},{"issue":"12","key":"ref67","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1538-7836.2010.04117.x","article-title":"Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease","volume":"8","author":"E Schwedhelm","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref68","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1089\/ars.2013.5527","article-title":"Statins as regulators of redox signaling in platelets","volume":"20","author":"F Violi","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"14","key":"ref69","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"P M Ridker","year":"1997","journal-title":"N Engl J Med"},{"issue":"08","key":"ref70","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.CIR.98.8.731","article-title":"Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women","volume":"98","author":"P M Ridker","year":"1998","journal-title":"Circulation"},{"issue":"21","key":"ref71","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"P M Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"02","key":"ref72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/CIRCRESAHA.108.190611","article-title":"Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques","volume":"105","author":"S U Eisenhardt","year":"2009","journal-title":"Circ Res"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2010.10.006","article-title":"Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia","volume":"214","author":"L Puccetti","year":"2011","journal-title":"Atherosclerosis"},{"issue":"01","key":"ref74","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ahj.2007.12.035","article-title":"An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration","volume":"156","author":"M Fisher","year":"2008","journal-title":"Am Heart J"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.bjp.0705907","article-title":"Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action","volume":"143","author":"D Taubert","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/cvr\/cvp120","article-title":"Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity","volume":"83","author":"P O'Kane","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0006-291X(03)01504-3","article-title":"Heme oxygenase-1 induction may explain the antioxidant profile of aspirin","volume":"308","author":"N Grosser","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"08","key":"ref78","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/01.ATV.0000083296.57581.AE","article-title":"Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway","volume":"23","author":"N Grosser","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"C557","DOI":"10.1152\/ajpcell.00045.2005","article-title":"Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells","volume":"289","author":"V Nascimento-Silva","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"issue":"04","key":"ref80","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1074248410375091","article-title":"A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans","volume":"15","author":"C H Hennekens","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1074248413482753","article-title":"Aspirin increases nitric oxide formation in chronic stable coronary disease","volume":"18","author":"S Hetzel","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1084\/jem.20040566","article-title":"15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation","volume":"200","author":"M J Paul-Clark","year":"2004","journal-title":"J Exp Med"},{"issue":"10","key":"ref83","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice","volume":"31","author":"U Laufs","year":"2000","journal-title":"Stroke"},{"issue":"10","key":"ref84","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1089\/ars.2008.2043","article-title":"Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities","volume":"10","author":"A Loboda","year":"2008","journal-title":"Antioxid Redox Signal"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.tcm.2013.09.006","article-title":"Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition","volume":"24","author":"F Violi","year":"2014","journal-title":"Trends Cardiovasc Med"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study","volume":"227","author":"E P Navarese","year":"2017","journal-title":"Int J Cardiol"},{"issue":"12","key":"ref87","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"J C Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"ref88","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"K Leander","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"ref89","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jacc.2017.07.779","article-title":"Exploration of PCSK9 as a cardiovascular risk factor: is there a link to the platelet?","volume":"70","author":"P A Gurbel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"07","key":"ref90","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical Pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"S Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"ref91","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/dom.12536","article-title":"Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials","volume":"17","author":"A Sahebkar","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"J D Horton","year":"2009","journal-title":"J Lipid Res"},{"issue":"25","key":"ref93","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"D W Zhang","year":"2007","journal-title":"J Biol Chem"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","article-title":"Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up","volume":"30","author":"C Barale","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"13","key":"ref95","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/cvr\/cvy128","article-title":"PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy","volume":"114","author":"Z Ding","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"04","key":"ref96","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"A A Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"ref97","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"M G Silverman","year":"2016","journal-title":"JAMA"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"C Werner","year":"2014","journal-title":"Vascul Pharmacol"},{"issue":"04","key":"ref99","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/antiox9040296","article-title":"PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation","volume":"9","author":"V Cammisotto","year":"2020","journal-title":"Antioxidants"},{"issue":"09","key":"ref100","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm1626","article-title":"Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype","volume":"13","author":"E A Podrez","year":"2007","journal-title":"Nat Med"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"R P Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"K Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"issue":"01","key":"ref103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","article-title":"Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9","volume":"34","author":"C A German","year":"2020","journal-title":"BioDrugs"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-med-080819-044918","article-title":"Treating coronary artery disease: beyond statins, ezetimibe, and PCSK9 inhibition","volume":"72","author":"K Musunuru","year":"2021","journal-title":"Annu Rev Med"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758654.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:32:20Z","timestamp":1675816340000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":104,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,2,7]]},"published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758654","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}